Azelastine, oxatomide and epinastine, dual PAF and histamine antagonists, have shown a remarkable effect of blocking PAF-induced bronchoconstriction in guinea pigs and rats [59,60,61] and its use is approved for asthma patients in Japan as an add-on treatment [62]. This evidence concerns the gene PCLAF and asthma.